Relieving the Weight: Fenfluramine's Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome [0.03%]
减重再显身手：芬氟拉明重新作为Lennox-Gastaut综合征和Dravet综合征的抗癫痫药物复苏应用
Simone A McCay,Harn J Shiue,Matthew T Hoerth
Simone A McCay
Objective: To review the pharmacology, usage, efficacy, and safety of fenfluramine in treating seizures in pediatric patients with Lennox-Gastaut syndrome or Dravet syndrome. ...
Reframing Persistence Metrics in Immune-Mediated Inflammatory Diseases: Toward Clinically Meaningful and Patient-Centered Outcomes in Medicine 6P Model [0.03%]
免疫介导的炎症性疾病中持久性指标的重构：医学6P模型中有意义和以患者为中心的结果方向
J Borrás-Blasco,Vicente Merino-Bohorquez,E Ramírez-Herráiz et al.
J Borrás-Blasco et al.
Remdesivir and Renal Outcomes in Hospitalized COVID-19 Patients Without Severe Renal Impairment: A Retrospective Cohort Study [0.03%]
关于住院的新冠肺炎非严重肾功能不全患者的瑞德西韦使用和肾脏结局：回顾性队列研究
Xiaotong Li,Kangho Suh,Na He et al.
Xiaotong Li et al.
Background: Remdesivir has demonstrated effect in reducing COVID-19 mortality and disease progression, while conflicting associations have been reported between remdesivir and renal outcomes. ...
Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan [0.03%]
靶向实体瘤中的TROP2：Datopotamab_deruxtecan的临床特征和作用
Rachel Lucky,Lauren Thornburg,Zachery Halford
Rachel Lucky
Objective: To evaluate the pharmacology, efficacy, safety, and clinical use of datopotamab deruxtecan (Dato-DXd), a recently approved trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), in t...
Crinecerfont: CRF1R Antagonist Approved for Treatment of Congenital Adrenal Hyperplasia [0.03%]
克林塞芬特：CRF1受体拮抗剂获批用于先天性肾上腺增生治疗
Lihui Yuan
Lihui Yuan
Objective: To review the pharmacology, efficacy, and safety profile of crinecerfont as adjunctive therapy in treating classic congenital adrenal hyperplasia (CAH). ...
Evaluation of Nurse-Managed Heparin Nomogram Adherence After Implementation of an Electronic Health Record-Embedded Heparin Calculator: An Antithrombotic Stewardship Initiative [0.03%]
嵌入式电子健康记录的肝素计算器实施后的护士管理肝素 nomogram 遵从性评估：抗血栓治疗管理的一项倡议
Taylor P Robichaux,Vi Gilmore,Erica Willits et al.
Taylor P Robichaux et al.
Background: Therapeutic intensity unfractionated heparin (UFH) infusions require titration to target a therapeutic activated partial thromboplastin time (aPTT) or UFH anti-Xa. At The Johns Hopkins Hospital (JHH) and Johns...
Relationship Between Patient's Body Mass Index and Dalbavancin's Effectiveness in the Treatment of Invasive Gram-Positive Infections [0.03%]
体重指数与达尔巴万cin治疗侵袭性阳性菌感染疗效之间的关系
Lisa Avery,Julia Kufel,Bruce Blaine et al.
Lisa Avery et al.
Background: Dalbavancin's pharmacokinetic parameters suggest obesity may affect serum and tissue concentrations, but currently there is no outcome data in the obese population with invasive infections. ...
Toripalimab and Penpulimab: Targeting PD-1 in Recurrent or Metastatic Nasopharyngeal Carcinoma [0.03%]
特瑞普利单抗和派安普利单抗：靶向PD-1治疗复发或转移性鼻咽癌
Josie J Hockett,Molly E Keller,David J Reeves
Josie J Hockett
Objective: The objective of this review is to evaluate clinical data regarding use of toripalimab and penpulimab use in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and to assess their impact on patient care....
Impact of 25% Albumin on Vasopressor Requirements in Critically Ill Patients Receiving Continuous Renal Replacement Therapy [0.03%]
人血白蛋白对连续性肾脏替代治疗重症患者血管活性药物需求的影响
Julia Lessing,Kelsey Stilley,Michelle Sharpe et al.
Julia Lessing et al.
Background: Critically ill patients receiving continuous renal replacement therapy (CRRT) commonly experience hypotension necessitating fluids, ultrafiltration (UF) adjustment, or vasopressors. There is limited evidence e...
Giuseppe Famularo,Marina Marini
Giuseppe Famularo